Skip to search formSkip to main contentSkip to account menu

1 ML Octreotide 0.1 MG/ML Injection

Known as: OCTREOTIDE ACETATE 100 ug in 1 mL SUBCUTANEOUS INJECTION, SOLUTION, OCTREOTIDE ACETATE 100 ug in 1 mL INTRAVENOUS INJECTION, SOLUTION, octreotide acetate 100 ug in 1 mL INTRAVENOUS INJECTION, SOLUTION [Octreotide Acetate] 
National Institutes of Health

Related topics

Related topics

20 relations
Acetic AcidAcromegalyAdenomaDiarrhea

Broader (1)

Antidiarrheals

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Synthesis, Characterization, and In Vitro Evaluation of New (99m)Tc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach.
Radiolabeled proteolytic degradation-resistant somatostatin analogues have been of long-standing interest as cancer imaging and… 
Review
2016
Review
2016
177 Lu-DOTA-Octreotate Therapy for Neuroendocrine Tumors: A Case Report and Review of the Literature
Favorable outcomes of peptide receptor radiotherapy of neuroendocrine tumors (NET) have been reported during the recent years. A… 
2015
2015
Treatment of pituitary tumours in 2014: Advances in therapy of adenomas secreting GH, ACTH and TSH
In 2014, many articles focusing on pituitary tumours were published, including studies on genetics, surgery, radiotherapy and… 
2013
2013
Palmitoylation of octreotide for incorporation into poly(amidoamine) dendrimers
Poly(amidoamine) (PAMAM) dendrimers are nano-sized carrier molecules with tremendous promise in polymeric drug delivery systems… 
2008
2008
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.
H-DPhe (2)-c[Cys (3)-Phe (7)-DTrp (8)-Lys (9)-Thr (10)-Cys (14)]-Thr (15)-NH2 (1) (a somatostatin agonist, SRIF numbering) and H… 
2006
2006
Δοσιμετρία κατά τις θεραπευτικές εφαρμογές με octreotide επισημασμένου με In-111
2005
2005
Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study
The aim of the present multicentric, open-label, non-comparative study was to evaluate the role of octreotide long-acting… 
Highly Cited
2003
Highly Cited
2003
Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
UNLABELLED Human somatostatin (SS) receptor (sst)-positive tumors can be visualized by gamma camera scintigraphy after the… 
2001
2001
Comparison of functional imaging and standard CT in evaluation of disease extent in patients with tumours showing neuroendocrine features.
BACKGROUND The diagnostic approach that should be used in disseminated neuroendocrine tumours (NET) remains a significant… 
2001
2001
[Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Acromegaly is caused by excessive secretion of growth hormone by a hypophyseal adenoma type of somatotropinoma. IGF-I is formed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)